Scarica l'app Stockscreener
18.21
1.76%
0.345
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$17.87
Aprire:
$17.96
Volume 24 ore:
450.54K
Relative Volume:
0.18
Capitalizzazione di mercato:
$2.46B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-8.9729
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-1.12%
1M Prestazione:
-5.00%
6M Prestazione:
-45.16%
1 anno Prestazione:
-48.02%
Intervallo 1D:
$17.74
$18.60
Intervallo di 1 settimana:
$17.15
$18.60
Portata 52W:
$16.10
$42.47
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
18.21 | 2.46B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.48 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.93 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
549.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.77 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharma general counsel Watson sells $93k in stock By Investing.com - Investing.com Canada
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
How To Trade (APLS) - news.stocktradersdaily.com
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth - Investing.com
Apellis at Goldman Sachs Conference: Strategic Insights on Product Growth By Investing.com - Investing.com Nigeria
Transcript : Apellis Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN
Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN - Yahoo
Wealth Enhancement Advisory Services LLC Has $1.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study - Yahoo Finance
Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study R - GuruFocus
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance
Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter
Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - MarketScreener
Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - MarketScreener
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - The Manila Times
Apellis Pharmaceuticals and Sobi Present Promising Phase 3 VALIANT Study Results for EMPAVELI in Treating Rare Kidney Diseases at European Renal Association Congress - Nasdaq
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire
Breakthrough: EMPAVELI Achieves 68% Disease Reduction in Rare Kidney Conditions as FDA Decision Approaches - Stock Titan
High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance
Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Ann - GuruFocus
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World
These 10 Stocks Blew Past Expectations - Insider Monkey
Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus
Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada
Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World
Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
5.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):